ETX 1153
Alternative Names: Amersib; Clostriban; eTS1153; ETX1153; ETX1153a; ETX1153b; ETX1153c; Mersanex; miconazole + nisinLatest Information Update: 04 Nov 2017
At a glance
- Originator e-Therapeutics
- Developer e-Therapeutics; Khandelwal Laboratories
- Class Antibacterials; Small molecules
- Mechanism of Action 14-alpha demethylase inhibitors; Cell membrane modulators; Cholesterol synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
- Discontinued Clostridium difficile infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in India (Topical)
- 16 Sep 2014 e-Therapeutics is looking for funding for ETX 1153c to resume development for Clostridium difficile infections
- 23 May 2014 ETX 1153 is available for licensing as of 23 May 2014. http://www.etherapeutics.co.uk/